Merus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.

About MRUS

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. 

CEO
Sven Ante Lundberg
CEOSven Ante Lundberg
Employees
260
Employees260
Headquarters
Utrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded
2003
Founded2003
Employees
260
Employees260

MRUS Key Statistics

Market cap
7.26B
Market cap7.26B
Price-Earnings ratio
-17.99
Price-Earnings ratio-17.99
Dividend yield
Dividend yield
Average volume
1.62M
Average volume1.62M
High today
$95.94
High today$95.94
Low today
$95.70
Low today$95.70
Open price
$95.90
Open price$95.90
Volume
1.69M
Volume1.69M
52 Week high
$96.28
52 Week high$96.28
52 Week low
$33.19
52 Week low$33.19

Stock Snapshot

With a market cap of 7.26B, Merus(MRUS) trades at $95.76. The stock has a price-to-earnings ratio of -17.99.

During the trading session on 2025-11-21, Merus(MRUS) shares reached a daily high of $95.94 and a low of $95.70. At a current price of $95.76, the stock is +0.1% higher than the low and still -0.2% under the high.

Trading volume for Merus(MRUS) stock has reached 1.69M, versus its average volume of 1.62M.

Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $96.28 and a low of $33.19.

Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $96.28 and a low of $33.19.

MRUS News

TipRanks 2d
Strategic Importance of Halozyme’s ENHANZE Platform and Its Growth Potential in Subcutaneous Drug Delivery

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme today and set a price target of $90.00. Meet Your ETF AI Analyst Discover how TipRan...

Nasdaq 4d
Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics

(RTTNews) - Monday, Merus N.V. (MRUS) has entered into a global non-exclusive collaboration and license agreement regarding Halozyme Therapeutics, Inc.'s ENHANZ...

Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics
TipRanks 4d
Merus, Halozyme enter collaboration, license agreement for petosemtamab

Merus (MRUS) and Halozyme Therapeutics (HALO) announced they have entered into a global non-exclusive collaboration and license agreement. Under the collaborati...

Analyst ratings

88%

of 17 ratings
Buy
11.8%
Hold
88.2%
Sell
0%

People also own

Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.